Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis.
Andriko PalmowskiCindy StrehlMoritz PfeiffenbergerThomas HäuplMartina SchadJim KallarackalUlrich ProthmannDenise DammannMark BoninAndreas BrandtUdo SchneiderTimo GaberFrank ButtgereitPublished in: Clinical rheumatology (2023)
Our prediction model constructed via genome-wide gene expression analysis in CD4 + and CD14 + mononuclear cells yielded excellent predictions. Our findings necessitate confirmation in other cohorts of MTX-naïve RA patients. Especially if used in conjunction with previously identified clinical and laboratory (bio)markers, our results could help predict response to MTX in RA to guide treatment decisions. Key Points • Patients with rheumatoid arthritis may or may not respond to treatment with methotrexate, which is the recommended first-line drug in guidelines around the world. • In non-responders, valuable time is lost until second-line treatments are started. • This study aimed at predicting response to methotrexate by identifying differentially expressed genes from peripheral blood samples. • The final prediction model yielded excellent prognostic values, but validation in other cohorts is necessary to corroborate these findings.
Keyphrases
- gene expression
- genome wide
- peripheral blood
- dna methylation
- high dose
- rheumatoid arthritis
- newly diagnosed
- ejection fraction
- end stage renal disease
- induced apoptosis
- disease activity
- emergency department
- systemic lupus erythematosus
- wastewater treatment
- clinical practice
- combination therapy
- signaling pathway
- patient reported outcomes
- nk cells
- smoking cessation
- idiopathic pulmonary fibrosis